SUPPLEMENTAL MATERIAL

Table S1. Variables used for propensity-score matching.

Author	Year	Valuables used for propensity-score matching
Ichibori et al. [26]	2017	Age, sex, New York Heart Association classification, previous percutaneous coronary intervention, estimated glomerular filtration rate and aortic valve area.
D'Ascenzo et al. [27]	2017	Pre-treatment covariates.

Table S2. Quality assessment of observational studies based on NOS (range, 1-9). NOS score≥8 is low risk, 6-7 is moderate risk and ≤5 is high risk.

Studies	Representativeness of exposed cohort	Selection of nonexposed cohort	Ascertainment of exposure	Absence of outcome at start of study	Comparability of cohorts	Outcome assessment	Length of follow-up	Adequacy of follow-up	NOS score
Poliacikova et al. [28]	1	1	1	1	1	1	1	1	8
Ichibori et al. [26]	1	1	0	1	2	0	1	1	8
D'Ascenzo et al. [27]	1	0	1	1	2	1	1	1	8

NOS=Newcastle-Ottawa Scale.

Figure S1. Search term.

EMBASE

1	transcatheter aortic valve implantation/	22597	Advanced	Display Results	More
2	dual antiplatelet therapy/	7225	Advanced	Display Results	More
3	antiplatelet.mp.	49979	Advanced	Display Results	More
4	clopidogrel/ or clopidogrel.mp.	63144	Advanced	Display Results	More
5	aspirin.mp. or acetylsalicylic acid/	228602	Advanced	Display Results	More
6	acetylsalicylic acid plus clopidogrel/	950	Advanced	Display Results	More
7	2 or 3 or 4 or 5 or 6	268230	Advanced	Display Results	More
8	TAVI.mp.	10584	Advanced	Display Results	More
9	TAVR.mp.	7727	Advanced	Display Results	More
10	1 or 8 or 9	24792	Advanced	Display Results	More
11	7 and 10	1192	Advanced	Display Results	More

Cochrane Central Resister of Controlled Trials

91 Trials matching **(transcatheter aortic valve) AND (antiplatelet OR antithrombotic OR aspirin or clopidogrel) in Title Abstract Keyword**

Cochrane Central Register of Controlled Trials

Pubmed

(transcatheter aortic valve) and (replacement or implant or implantation) and (antiplatelet or antithrombic or aspirin or clopidogrel)

Figure S2. Risk of bias summary according to the Cochrane Collaboration Manual.

Yellow: unclear risk; Green: low risk (A) and risk of bias graph according to the Cochrane Collaboration Manual (B).

A



B



Figure S3. Antiplatelet therapy and risk of major or life-threatening bleeding (random-effects model) of sensitivity analysis including only 4 randomized controlled trials.



CI=confidence interval, DAPT=dual antiplatelet therapy, RR=risk ratio, SAPT=single antiplatelet therapy.

Figure S4. Antiplatelet therapy and risk of stroke (random-effects model) of sensitivity analysis including only 4 randomized controlled trials.



CI=confidence interval, DAPT=dual antiplatelet therapy, RR=risk ratio, SAPT=single antiplatelet therapy.

Figure S5. Antiplatelet therapy and risk of all-cause mortality (random-effects model) of sensitivity analysis including only 4 randomized controlled trials.



CI=confidence interval, DAPT=dual antiplatelet therapy, RR=risk ratio, SAPT=single antiplatelet therapy

Figure S6. Funnel plot for each analysis. A: Major or life-threatening bleeding; B: Stroke; C: All-cause mortality; D: Major or life-threatening bleeding (sensitivity analysis); B: Stroke (sensitivity analysis); C: All-cause mortality (sensitivity analysis).

A



B


SAPT:DAPT3
SAPT:DAPT6
Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.1
0.2
0.5
1.0
2.0
5.0
10.0
Risk Ratio centered at
comparison-specific effect

C


SAPT:DAPT3
SAPT:DAPT6
Standard Error
0.0
0.2
0.4
0.6
0.8
0.2
0.5
1.0
2.0
5.0
Risk Ratio centered at
comparison-specific effect

D


SAPT:DAPT3
SAPT:DAPT6
Standard Error
0.0
0.2
0.4
0.6
0.5
1.0
2.0
Risk Ratio centered at
comparison-specific effect

E


SAPT:DAPT3
SAPT:DAPT6
Standard Error
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.1
0.2
0.5
1.0
2.0
5.0
10.0
Risk Ratio centered at
comparison-specific effect

F


SAPT:DAPT3
SAPT:DAPT6
Standard Error
0.0
0.2
0.4
0.6
0.8
0.2
0.5
1.0
2.0
5.0
Risk Ratio centered at
comparison-specific effect